Latest filing published 15 May 2026 for Karyopharm Therapeutics Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Reshma Rangwala, listed as senior executive, appears in our data through filings on Karyopharm Therapeutics Inc. shares, published by SEC (Form 4). In total, 15 filings cover trades dated from 29 April 2022 to 13 May 2026.
On the market, this insider has only sold: 7 sales, €93k in total. Besides market trades, the filings include 8 share grants. So far in 2026, the count stands at no purchases and 2 sales.
The latest filing, published on 15 May 2026, reports a share grant in Karyopharm Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations